Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do not meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success

Annals of Surgery

Volumn 260, Issue 4, 2014, Pages 617-624

  Parikh, Manish ^a   Chung, Mimi ^a   Sheth, Sheetal ^a   McMacken, Michelle ^a   Zahra, Tasneem ^b   Saunders, John K ^a   UdeWelcome, Aku ^a   Dunn, Van ^c   Ogedegbe, Gbenga ^d   Schmidt, Ann Marie ^a   Pachter, H Leon ^a  

^a Biostatist Epidemiol St Jude C   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Lincoln Hospital   (United States)

^d Health and Hospitals Corporation   (United States)

Author keywords

Bariatric surgery; BMI under 35; Diabetes; Obesity; SRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN RECEPTOR;

ADULT; BARIATRIC SURGERY; BODY MASS; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES EDUCATION; DIABETIC PATIENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL COUNSELING; OBESITY; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PHYSICAL ACTIVITY; PILOT STUDY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SELF MONITORING; SLEEVE GASTRECTOMY; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT REDUCTION; ARTICLE; CONTROLLED CLINICAL TRIAL; COUNSELING; KINESIOTHERAPY; MIDDLE AGED;

ADULT; BARIATRIC SURGERY; BIOLOGICAL MARKERS; BODY MASS INDEX; COUNSELING; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; RECEPTORS, IMMUNOLOGIC; REMISSION INDUCTION; WEIGHT LOSS;

EID: 84908338020     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000919     Document Type: Conference Paper

References (28)

1. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-256.
2. Gastrointestinal Surgery for Severe Obesity. National Institutes of Health Consensus Development Conference Statement, March 25-27, 1991. http://consensus.nih.gov/1991/1991GISurgeryObesity084html.htm. Accessed August 9, 2014.
3. Bays HE, Chapman RH, Grandy S, et al. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737-747.
4. Maglione MA, Maggard Gibbons M, Livhits M, et al. Bariatric Surgery and Nonsurgical Therapy in Adults With Metabolic Conditions and a Body Mass Index of 30.0 to 34.9 kg/m2. Comparative Effectiveness Review No. 82. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I.) AHRQ Publication No. 12(13)-EHC139-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
5. Cummings D. Metabolic surgery for type 2 diabetes. Nature Med. 2012; 18:656-658.
6. Basta G, Lazerrini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105:816-822.
7. Song F, Hurtado del Pozo C, Rosario R, et al. RAGE regulates the metabolic and inflammatory response to high fat feeding in mice. Diabetes. 2014;63: 1948-1965.
8. Brix J, Hollerl F, Kopp H, et al. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. Inter J Obesity. 2012:36:1412-1417.
9. Ramasamy R,Yan S, Schmidt A.RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol. 2009;86:505-512.
10. Boutron I,Moher D, Altman DG, et al. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148:295-309.
11. KnowlerW, Barrett-Connor E, Fowler S, et al. for the Diabetes Prevention Program. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
12. Pi-Sunyer X, Blackburn G, Brancati F, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care. 2007;30:1374-1383.
13. Tuomilehto J, Lindstrom J, Eriksson J, et al. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
14. Wadden T, Berkowitz R,Womble L, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111-2120.
15. Parikh M, Dasari M, McMacken M, et al. Does a preoperative medically supervised weight loss program improve bariatric surgery outcomes? A pilot randomized study. Surg Endosc. 2012;26:853-861.
16. Parikh M, Issa R, McCrillis A, et al. Surgical strategies that may decrease leak after laparoscopic sleeve gastrectomy: a systematic review and meta-analysis of 9991 cases. Ann Surg. 2013;257:231-237.
17. Aills L, Blankenship J, Buffington C, et al. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis. 2008;4:S73-108.
18. Shen R, Dugay G, Rajaram K, et al. Impact of patient follow-up on weight loss after bariatric surgery. Obes Surg. 2004;14:514-519.
19. Selvin E, Steffes M, Zhu H, et al. Glycated hemoglobin, diabetes and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800-811.
20. Robinson J, Lupkiewicz S, Palenik L, et al. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983;40:1016-1019.
21. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.
22. Parikh M, Issa R, Vieira D, et al. The role of bariatric surgery in the treatment of type 2 diabetes in patients who do not meet current NIH criteria (BMI
23. Schauer P, Kashyap S,Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. New Engl J Med. 2012;366:1567-1576.
24. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventionalmedical therapy for type 2 diabetes. N Engl JMed. 2012;366:1577-1585.
25. Ikramuddin S, Korner J, Lee W, et al. Roux-en-Y gastric bypass vs. intensive medical management for the control of type 2 diabetes, hypertension and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240-2249.
26. DePaula A, Stival A, Macedo A, et al. Prospective randomized controlled trial comparing 2 version of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34. Surg Obes Relat Dis. 2010;6:296-305.
27. Lee W, Chong K, Kong-Han S, et al. Gastric bypass vs. sleeve gastrectomy for type 2 diabetes mellitus. A randomized controlled trial. Arch Surg. 2011;146:143-148.
28. Arteburn D, Flum D,Westbrook E, et al. A population-based, shared decisionmaking approach to recruit for a randomized trial of bariatric surgery versus lifestyle for type 2 diabetes. Surg Obes Relat Dis. 2013;9:837-844.